ClinicalTrials.gg
CompletedNCT04710875LILACHUpdated Jan 24, 2022

The Role of Lactate in Lipolysis and Catabolism in Humans

An interventional study of Na-lactate and Sodium chloride in Hyperlactatemia, Healthy and Lactate, sponsored by University of Aarhus. Completed at 2 sites in Denmark. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-24.

Sponsored by University of Aarhus · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Lactate may have anti-lipolytic effects when plasma concentrations of lactate reach levels similar to those seen during high intensity exercise.

This study aims to investigate how lactate concentrations similar to those achieved during high intensity exercise affects lipolysis in humans. In addition to this, to investigate how increased lactate concentrations affects glucose- and amino acid metabolism.

8 healthy males will be included. Study participants will undergo two separate investigation days that will be identical except for the interventions:

  1. Intravenous sodium D/L-lactate
  2. Intravenous sodium chloride.

The study consists of a 3-hour basal period followed by a 3-hour hyperinsulinemic euglycemic clamp. During the study we will:

  • Estimate insulin sensitivity during the hyperinsulinemic euglycemic clamp (M value)
  • Use tracer kinetics to estimate lipid-, glucose and amino acid metabolism using [9,10-3H]-palmitate, [3-3H]-glucose, [15N]-phenylalanine, [15N]-tyrosine, [2H4]-tyrosine and [13C]-Urea.
  • Do muscle- and adipose tissue biopsies for analyses of signaling pathways involved in regulation of lipid-, glucose and amino acid metabolism.
  • Do blood samples of relevant hormones, metabolites and cytokines.
  • Use indirect calorimetry to estimate study participants' resting energy expenditure and respiratory quotient during the basal period.
  • Estimate cardiac ejection fraction by echocardiography and measure blood pressure during both the basal- and clamp period.
02

Conditions studied

  • Hyperlactatemia
  • Healthy
  • Lactate

Browse trials for

Keywords

  • Lipolysis
  • Catabolism
  • Glucose metabolism
  • Aminoacid metabolisme
03

In context

Hyperlactatemia

50 studies on the registry are indexed under Hyperlactatemia; 7 are open to participants now.

This study's enrollment of 8 is below the median of 38 across 32 interventional studies indexed under Hyperlactatemia.

Browse Hyperlactatemia studies →

Lead sponsor

University of Aarhus is the lead sponsor of 1,300 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male
  • >18 years of age
  • >19 and below 30
  • Written and verbal consent to participation

Exclusion criteria

Exclusion Criteria:

  • Chronic illness
  • daily use of medicine
  • affected blood samples at screening, as assessed by the PI
  • does not speak and understand Danish
  • Assessed unsuitable by PI.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
8 participants (actual)

Study arms

  • Active comparator
    Na-lactate

    Iv infusion of sodium D/L lactate

    Drug: Na-lactate

  • Placebo comparator
    Sodium chloride

    Iv infusion of Sodium chloride

    Drug: Sodium chloride

Interventions

  • intravenous

    Also known as: Sodium lactate

  • DrugSodium chloride

    Intravenous

    Also known as: NaCl

06

What researchers measure

Primary outcomes

  1. Acute Metabolic effects of Na-lactate compared with NaCl on lipolysis

    Change in \[9,10-3H\]-palmitate tracer flux

    Time frame: 2 hours (1 hour basal period, 1 hour clamp)

Secondary outcomes

  1. Acute Metabolic effects of Na-lactate compared with NaCl on glucose metabolism

    Change in glucose metabolism quantified with \[3-3H\]-glucose tracer

    Time frame: 6 hours (3 hours basal period, 3 hours clamp)

  2. Insulin sensitivity

    Hyperinsulinaemic euglycaemic clamp with 0.6mU/kg/min insulin and 20% glucose to calculate M value. Difference between interventions.

    Time frame: 3 hours.

  3. Acute metabolic effects of Na-lactate compared with NaCl on aminoacid metabolism

    Change in aminoacid metabolism quantified with \[15N\]-phenylalanine, \[15N\]tyrosine, \[2H4\]tyrosine and \[13C\]-Urea tracers.

    Time frame: 6 hours

  4. Indirect calorimetry during clamp

    Change in estimation of resting energy expenditure during clamp. Difference between interventions.

    Time frame: 20 minutes

  5. Indirect calorimetry during basal conditions

    Change in estimation of respiratory quotient during basal period. Difference between interventions.

    Time frame: 20 minutes

  6. Echocardiography

    Change in cardiac ejection fraction during basal period. Difference between interventions.

    Time frame: 15 minutes

  7. Echocardiography

    Change in cardiac ejection fraction during clamp period. Difference between interventions.

    Time frame: 15 minutes

  8. blood pressure

    blood pressure (systolic and diastolic) during basal- and clamp

    Time frame: 2 x 10 min

  9. Blood samples - Insulin

    Insulin concentrations. Difference between interventions.

    Time frame: 6 hours.

  10. Blood samples - c-peptid

    c-peptid concentrations. Difference between interventions.

    Time frame: 6 hours.

  11. Blood samples - glucagon

    glucagon concentrations. Difference between interventions.

    Time frame: 6 hours.

  12. Blood samples - cortisol

    cortisol concentrations. Difference between interventions.

    Time frame: 6 hours.

  13. Blood samples - Ghrelin

    Ghrelin concentrations. Difference between interventions.

    Time frame: 6 hours.

  14. Blood samples - GDF-15

    GDF-15 concentrations. Difference between interventions.

    Time frame: 6 hours.

  15. Blood samples - free fatte acids

    Free fatte acids concentrations. Difference between interventions.

    Time frame: 6 hours.

  16. Blood samples - glucose

    glucose concentrations. Difference between interventions.

    Time frame: 6 hours.

  17. Blood samples - lactate

    lactate concentrations. Difference between interventions.

    Time frame: 6 hours.

  18. Changes in signaling in muscle tissue between interventions

    Western blot examinations of muscle tissue biopsies

    Time frame: After 3 and 5 hours of intervention

  19. Changes in signaling in adipose tissue between interventions

    Western blot examinations of adipose tissue biopsies

    Time frame: After 3 and 5 hours of intervention

07

Study locations

2 sites
  • Medical/Steno Aarhus research laboratory
    Aarhus, Central Region Denmark 8200, Denmark
  • Aarhus University Hospital
    Aarhus N, 8200, Denmark
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jun 2021, 3 months.

Of 17 interventional studies with no phase under Hyperlactatemia, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Jan 15, 2021
StartActual
Mar 10, 2021
Primary completionActual
Jun 29, 2021
CompletionActual
Jun 29, 2021
Last update
Jan 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04710875
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Mar 10, 2021
Primary completion
Jun 29, 2021
Completion
Jun 29, 2021
Last update
Jan 24, 2022

Study contacts

Niels Møller, Prof, MD, DMSc
study director · Medical/Steno Aarhus research laboratory, Aarhus University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Lactate

Start the discussion